Equities

ReNeuron Group PLC

ReNeuron Group PLC

Actions
  • Price (EUR)0.428
  • Today's Change-0.008 / -1.83%
  • Shares traded0.00
  • 1 Year change-69.86%
  • Beta--
Data delayed at least 15 minutes, as of May 19 2022 19:34 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based cell-based therapeutics company. The Company develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate.

  • Revenue in GBP (TTM)274.00k
  • Net income in GBP-9.49m
  • Incorporated2005
  • Employees43.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttp://www.reneuron.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.